Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age
Conditions
HIV-1-infection
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Site 5030, Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States
Site 6501, St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States
Site 12701, Gaborone CRS, Gaborone, Botswana
Site 12702, Molepolole CRS, Gaborone, Botswana
Site 5073, SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Brazil
CRS 5071, Instituto de Puericultura e Pediatria Martagao Gesteira Clinical Research Site, Rio de Janeiro, Brazil
Site 30300 Umlazi CRS Site, Umlazi, KwaZulu-Natal, South Africa
Contact: Study coordinator (Zulaykha Sarally-Moideen, MD) · sarally-moideen@caprisa.org · 27-31-6550811CRS 8052, Soweto IMPAACT, Johannesburg, South Africa
Site 8051, Wits RHI Shandukani Research Centre CRS, Johannesburg, South Africa
Siriraj Hospital, Mahidol University NICHD CRS (Site #5115), Bangkok, Bangkoknoi, Thailand
Contact: Study coordinator (Kulkanya Chokephaibulkit, MD) · Kulkanya.cho@mahidol.ac.th · 66-2-866-0225CRS 31784, Chiang Mai University HIV Treatment CRS, Chiang Mai, Thailand
Site 5116, Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Rai, Thailand